Zogenix, Inc. (NASDAQ:ZGNX) – Leerink Swann issued their FY2017 EPS estimates for shares of Zogenix in a research note issued on Sunday, according to Zacks Investment Research. Leerink Swann analyst G. Porges forecasts that the company will post earnings of ($4.17) per share for the year. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Zogenix’s Q4 2017 earnings at ($0.80) EPS, Q1 2018 earnings at ($0.77) EPS, Q2 2018 earnings at ($0.85) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.98) EPS, FY2018 earnings at ($3.09) EPS and FY2019 earnings at ($1.56) EPS.
Other research analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Mizuho restated a “buy” rating and issued a $51.00 target price on shares of Zogenix in a report on Thursday, December 7th. ValuEngine upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, January 27th. Finally, JMP Securities started coverage on shares of Zogenix in a report on Monday, November 27th. They issued an “outperform” rating and a $56.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $46.40.
Shares of Zogenix (NASDAQ:ZGNX) remained flat at $$44.50 during trading on Wednesday. 211,104 shares of the company’s stock traded hands, compared to its average volume of 601,354. Zogenix has a 12 month low of $10.00 and a 12 month high of $45.85. The firm has a market cap of $1,530.00, a price-to-earnings ratio of -12.63 and a beta of 1.57.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.17). Zogenix had a negative net margin of 309.76% and a negative return on equity of 81.65%. During the same quarter in the previous year, the company earned ($0.95) earnings per share.
A number of large investors have recently modified their holdings of ZGNX. Stifel Financial Corp acquired a new stake in Zogenix during the 2nd quarter worth $175,000. Voya Investment Management LLC boosted its stake in Zogenix by 13.5% during the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock worth $205,000 after purchasing an additional 1,686 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Zogenix during the 3rd quarter worth $226,000. Sterling Capital Management LLC acquired a new stake in Zogenix during the 3rd quarter worth $237,000. Finally, Alliancebernstein L.P. boosted its stake in Zogenix by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock worth $258,000 after purchasing an additional 2,500 shares during the period.
TRADEMARK VIOLATION WARNING: “Leerink Swann Weighs in on Zogenix, Inc.’s FY2017 Earnings (ZGNX)” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/03/14/zogenix-inc-forecasted-to-post-fy2017-earnings-of-4-17-per-share-zgnx.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.